Pharmacology, Toxicology, and Biochemistry Department, Faculty of Pharmacy, Future University in Egypt, Cairo, Egypt.
Pharmacology and Toxicology Department, Faculty of Pharmacy, Cairo University, Cairo, Egypt.
Life Sci. 2021 Aug 15;279:119697. doi: 10.1016/j.lfs.2021.119697. Epub 2021 Jun 5.
Vitamin D and rosuvastatin are well-known drugs that mediate beneficial effects in treating type-2 diabetes (T2D) complications; however, their anti-neuropathic potential is debatable. Hence, our study investigates their neurotherapeutic potential and the possible underlying mechanisms using a T2D-associated neuropathy rat model.
Diabetic peripheral neuropathy (DPN) was induced with 8 weeks of administration of a high fat fructose diet followed by a single i.p. injection of streptozotocin (35 mg/kg). Six weeks later, DPN developed and rats were divided into five groups; viz., control, untreated DPN, DPN treated with vitamin D (cholecalciferol, 3500 IU/kg/week), DPN treated with rosuvastatin (10 mg/kg/day), or DPN treated with combination vitamin D and rosuvastatin. We determined their anti-neuropathic effects on small nerves (tail flick test); large nerves (electrophysiological and histological examination); neuronal inflammation (TNF-α and IL-18); apoptosis (caspase-3 activity and Bcl-2); mitochondrial function (NRF-1, TFAM, mtDNA, and ATP); and NICD1, Wnt-10α/β-catenin, and TGF-β/Smad-7 pathways.
Two-month treatment with vitamin D and/or rosuvastatin regenerated neuronal function and architecture and abated neuronal inflammation and apoptosis. This was verified by the inhibition of the neuronal content of TNF-α, IL-18, and caspase-3 activity, while augmenting Bcl-2 content in the sciatic nerve. These treatments inhibited the protein expressions of NICD1, Wnt-10α, β-catenin, and TGF-β; increased the sciatic nerve content of Smad-7; and enhanced mitochondrial biogenesis and function.
Vitamin D and/or rosuvastatin alleviated diabetes-induced neuropathy by suppressing Notch1 and Wnt-10α/β-catenin; modulating TGF-β/Smad-7 signaling pathways; and enhancing mitochondrial function, which lessened neuronal degeneration, demyelination, and fibrosis.
维生素 D 和瑞舒伐他汀是两种众所周知的药物,它们在治疗 2 型糖尿病(T2D)并发症方面具有有益作用;然而,它们的抗神经病变潜力仍存在争议。因此,我们使用与 2 型糖尿病相关的周围神经病变大鼠模型来研究它们的神经治疗潜力和可能的潜在机制。
通过给予高脂肪果糖饮食 8 周,随后单次腹腔注射链脲佐菌素(35mg/kg)诱导糖尿病周围神经病变(DPN)。6 周后,DPN 发生,将大鼠分为五组:对照组、未治疗的 DPN 组、DPN 用维生素 D(胆钙化醇,3500IU/kg/周)治疗组、DPN 用瑞舒伐他汀(10mg/kg/天)治疗组或 DPN 用维生素 D 和瑞舒伐他汀联合治疗组。我们通过尾部拍打试验测定了它们对小神经(尾部拍打试验)、大神经(电生理学和组织学检查)、神经元炎症(TNF-α 和 IL-18)、细胞凋亡(caspase-3 活性和 Bcl-2)、线粒体功能(NRF-1、TFAM、mtDNA 和 ATP)以及 NICD1、Wnt-10α/β-catenin 和 TGF-β/Smad-7 途径的抗神经病变作用。
用维生素 D 和/或瑞舒伐他汀治疗两个月可使神经元功能和结构再生,并减轻神经元炎症和细胞凋亡。这是通过抑制 TNF-α、IL-18 和 caspase-3 活性在坐骨神经中的含量,同时增加 Bcl-2 含量来证实的。这些治疗方法抑制了 NICD1、Wnt-10α、β-catenin 和 TGF-β 的蛋白表达,增加了坐骨神经中 Smad-7 的含量,并增强了线粒体的生物发生和功能。
维生素 D 和/或瑞舒伐他汀通过抑制 Notch1 和 Wnt-10α/β-catenin;调节 TGF-β/Smad-7 信号通路;以及增强线粒体功能,减轻神经元变性、脱髓鞘和纤维化,从而缓解糖尿病引起的神经病变。